author-photo

Hendrik-Tobias Arkenau

Sarah Cannon Research Institute
University College London
The Royal Marsden NHS Foundation Trust

222

Papers

5084

Citations

Citation Trend

Filter By

Papers (222) Sort By

Journal Conference Others

Association of combined phase I/II study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with Nectin-4 expression.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (20)
A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma.

2021 Critical Reviews in Oncology Hematology
Show All
- Source
- Cite
- Save
Citations (2)
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer

2021 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.

2021 Clinical Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)
Health-related quality of life in patients with advanced colorectal cancer: a predictive nomogram including BMI, sex and age.

2021 Annals of palliative medicine
Show All
- Source
- Cite
- Save
Citations (0)
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.

2021 Gastric Cancer
Show All
- Source
- Cite
- Save
Citations (1)
A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.

2021 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (0)
Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study.

2021 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (0)